Courtenay C. Brinckerhoff

Partner

Courtenay C. Brinckerhoff

Partner

Courtenay Brinckerhoff is an intellectual property lawyer, assisting international clients with all aspects of obtaining, defending, evaluating, licensing, and enforcing patents; and conducting freedom-to-operate and due diligence investigations. She is a partner and vice chair of the firm’s Intellectual Property Department, as well as the editor and primary author for Foley’s PharmaPatentsBlog.com, where she analyzes evolving patent office practices and precedential court decisions on emerging legal issues.

For more than 25 years, Courtenay has represented clients in diverse industries before the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit. She has successfully represented clients in complex patent matters, including four-party interference, Inter partes Reexaminations, Inter partes Reviews, and ANDA litigation.

Courtenay works with clients across the chemical and biotechnology industries, including on innovations for pharmaceuticals and drug-device products, human and animal food products and nutraceuticals, and industrial technologies. Clients trust Courtenay to secure critical intellectual patent rights, including patents intended for listing in the Orange Book or eligible for listing in the Purple Book.

She has particular experience with transdermal pharmaceutical products (patches, gels, and liquids), oral dosage forms (including controlled/extended-release formulations), enzyme-based technologies, microbial technologies, diagnostic and therapeutic antibodies, active and passive immunization therapies, and personalized medicine, as well as with industrial films, carbon nanotube technologies, biofuels, and carbon capture technologies.

Courtenay has served as vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and is an active member of the firm’s PTAB Trials Practice and Life Sciences Industry Team.

Prior to joining Foley as an associate, Courtenay clerked for the Honorable Alvin Anthony Schall on the U.S. Court of Appeals for the Federal Circuit. Prior to her clerkship, she worked at Foley as a patent agent and law clerk.

Awards and Recognition

  • Stand-out Lawyer, Thomson Reuters (2025)
  • The Best Lawyers in America©, Patent Law (2021-2024) and Biotechnology and Life Sciences Practice (2023-2024)
  • IP Distinguished Alumni Award from George Mason University Antonin Scalia Law School (April 2017)
  • JD Supra Readers’ Choice Top Author (2017-2021) in the categories of pharmaceutical industry and patents for her work on the PharmaPatents blog
  • IAM Patent 1000 – The World’s Leading Patent Practitioners, patent prosecution (2014-2016, 2020-2021, 2024)
  • Top Women in IP, Managing IP (2015)
  • IP Star, Managing IP (2015)

Thought Leadership

Courtenay writes and speaks on topics important to clients in chemical, biotechnological, pharmaceutical, food, and personalized medicine industries. She has been an invited speaker at the AIPLA Annual Meeting, the FDLI Annual Meeting, the Intellectual Property Owner’s Association annual meeting, the PTAB Bar Association annual meeting, and the annual Advanced Patent Law Institute presented by the University of Texas School of Law, the United States Patent and Trademark Office, and George Mason University Antonin Scalia Law School.

Courtenay currently serves as a Vice Chair of the Intellectual Property Owner’s Association Patent Office Practice Committee and as a Vice Chair of the Appeals to the PTAB Committee of the PTAB Bar Association.

Courtenay has been following U.S. patent reform since its inception, and she and other Foley colleagues co-authored the treatise, America Invents Act: Law & Analysis (Wolters Kluwer 2012). The interface between patent law and FDA law is another area of interest, and she has written and spoken on issues including patent term extension, the scope of the Hatch-Waxman “safe harbor,” the ANDA litigation framework, and the biosimilars BPCIA framework.

 

24 March 2025 PharmaPatents

Federal Circuit Decision Could Encourage More Reissue Patents

The Patent Term Extension provisions of 35 U.S.C. § 156 compensate pharmaceutical patent owners for time they are not able to enjoy commercial market exclusivity because their products are not yet approved by the U.S. Food and Drug Administration.
17 March 2025 PharmaPatents

Delaying Examination of Continuing Applications Could Sabotage USPTO Goals

Rumor has it that one of many behind-the-scenes changes being implemented at the USPTO relates to how (or when) continuing applications are taken up for examination.
11 March 2025 PharmaPatents

Leveraging USPTO Delays To Maximize Patent Term

Before the USPTO was subject to a hiring freeze, it assumed it would onboard 400 new examiners between fiscal year 2025 and fiscal year 2026, and still predicted an increase in the backlog of unexamined patent applications.
20 January 2025 PharmaPatents

Federal Circuit Says Proper Orange Book-Listed Patent Must Claim Active Ingredient

In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, the Federal Circuit jumped on the bandwagon of scrutinizing the types of patents that can be listed in the Food & Drug Administration (FDA) Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), and decided that the “device” patents at issue were not properly listable.
20 November 2024 PharmaPatents

USPTO Publishes Final Fees for 2025

The USPTO has published its final rule setting patent fees that will take effect January 19, 2025.
04 October 2024 PharmaPatents

USPTO Puts an End to After-Final Pilot Program

The U.S. Patent and Trademark Office (USPTO) has announced that its “After Final Consideration Pilot Program 2.0” (“AFCP 2.0”) will come to an end on December 14, 2024.